Combination of antiangiogenic and systemic therapy in advanced non-small cell lung cancer: before and after progression to leptomeningeal metastasis.

ABSTRACT: Leptomeningeal metastasis (LM) is the most devastating complication of non-small cell lung cancer (NSCLC), and its incidence is increasing. We investigated the survival outcomes of patients with NSCLC who received combined antiangiogenic and systemic therapies before and after LM progression and explored survival-associated factors. Patients with epidermal growth factor receptor (EGFR)-mutant or wild-type NSCLC-LM receiving systemic therapy were included. Survival outcomes were analyzed separately for patients who received different therapies before and after LM progression. The primary outcomes were the median time from NSCLC diagnosis to LM (LM-free survival [mLFS]) and overall survival (mOS). The mLFS and mOS of the 77 enrolled patients after receiving EGFR-tyrosine kinase inhibitor (TK

SUBMITTER: Zhu XD 

PROVIDER: S-EPMC11976944 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature